跳至主要内容
临床试验/NCT06105671
NCT06105671已完成不适用

Physiological Responses to U-LABA/ICS With Emphasis on Exercise Performance in Well-Trained Individuals, Formoterol

Morten Hostrup, PhD1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年1月5日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
20
试验地点
1
主要终点
Power output during time trial

研究概览

简要总结

The purpose of the project is to investigate exercise performance in well-trained individuals in a crossover design following varying degrees of bronchodilation/constriction intervention using current standard procedures.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18-45
  • Physically active >5 hours a week
  • Maximum oxygen uptake classified as high or very high

排除标准

  • Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid
  • ECG abnormality
  • FEV1/FVC ratio < 0,7 determined with spirometry
  • Chronic illness determined to be a potential risk for participant during the study
  • In chronic treatments with medication that may interfere with study results
  • Pregnancy
  • Blood donation during the past 3 months

研究组 & 干预措施

Symbicort - usual care

Experimental

Participants are administered Formoterol + Budesonide from an inhaler device testing. In addition, participants are administered a placebo capsule, which is taken orally.

干预措施: Symbicort (Drug)

Formoterol - inhalation

Experimental

Participants are administered Formoterol from an inhaler device testing. In addition, participants are administered a placebo capsule, which is taken orally.

干预措施: Formoterol (Drug)

Formoterol - oral

Experimental

Participants are administered a Formoterol capsule, which is taken orally. In addition, participants are administered placebo from an inhaler device.

干预措施: Formoterol (Drug)

Placebo

Placebo Comparator

Participants are administered placebo from an inhaler device testing and a placebo capsule.

干预措施: Placebo (Drug)

Mannitol-test

Experimental

Participants are administered Bronchitol from an inhaler device testing.

干预措施: Mannitol (Drug)

结局指标

主要结局

Power output during time trial

时间窗: Through study completion, an average on 4 weeks

Mean power output measured in Watts during a time trial on a bike ergometer

次要结局

  • Power output during sprint testing(Through study completion, an average on 4 weeks)

研究者

发起方
Morten Hostrup, PhD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Morten Hostrup, PhD

Associate Professor

University of Copenhagen

研究点 (1)

Loading locations...

相似试验